Table 3.
Incidence of severe irAE and estimated percentage of incidence with exact 95% confidence interval.
| Cohort | Number of severe irAE | Number of subjects | Estimated percent of incidence | 95% exact CI |
|---|---|---|---|---|
| All | 29 | 284 | 10.2 | (6.9, 14.3) |
| Bladder | 6 | 40 | 15.0 | (5.7, 29.8) |
| Gynecologic | 0 | 15 | 0.0 | (0, 21.8) |
| Head & Neck | 0 | 15 | 0.0 | (0, 21.8) |
| Hepatocellular carcinoma | 1 | 19 | 5.3 | (0.1, 26) |
| Melanoma | 10 | 118 | 8.5 | (4.1, 15) |
| Renal cell carcinoma | 11 | 58 | 19.0 | (9.9, 31.4) |
| Squamous cell carcinoma | 1 | 19 | 5.3 | (0.1, 26) |
irAE = Immune-mediated adverse effect.
CI = Confidence interval.